AbbVie’s schizophrenia treatment crumbles, boosting Bristol Myers Squibb to the top

Bristol Myers Squibb's stock surged dramatically after pharmaceutical giant AbbVie announced disappointing results in its recent clinical trials for a promising schizophrenia drug. The development ... Read More